LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

Search

Ascendis Pharma A-S ADR

Cerrado

SectorSalud

211.74 2.46

Resumen

Variación precio

24h

Actual

Mínimo

210.14

Máximo

215.61

Métricas clave

By Trading Economics

Ingresos

-22M

-61M

Ventas

56M

214M

Margen de beneficio

-28.549

Empleados

1,017

EBITDA

-56M

-53M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+25.9% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

927M

13B

Apertura anterior

209.28

Cierre anterior

211.74

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Ascendis Pharma A-S ADR Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

24 dic 2025, 21:41 UTC

Adquisiciones, fusiones, absorciones

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

24 dic 2025, 14:57 UTC

Adquisiciones, fusiones, absorciones

Accenture to Acquire Cabel Industry from Fibonacci Group

24 dic 2025, 12:48 UTC

Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

Repare Therapeutics Shares Rise on $30 Million Asset Deal With Gilead

24 dic 2025, 12:21 UTC

Principales Movimientos del Mercado

Nike Shares Tick Up After Apple CEO Tim Cook Buys $2.9 Million of Its Stock

24 dic 2025, 22:22 UTC

Adquisiciones, fusiones, absorciones

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

24 dic 2025, 21:26 UTC

Adquisiciones, fusiones, absorciones

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

24 dic 2025, 19:35 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

24 dic 2025, 19:35 UTC

Charlas de Mercado

Treasury Yields Decline Ahead of Christmas -- Market Talk

24 dic 2025, 19:09 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Global Equities Roundup: Market Talk

24 dic 2025, 19:09 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

ServiceNow's Armis Acquisition Shouldn't Fuel Fears That Seat-Based Model Threatened -- Market Talk

24 dic 2025, 19:06 UTC

Charlas de Mercado

Oil Futures Little Changed in Light Pre-Holiday Trade -- Market Talk

24 dic 2025, 19:03 UTC

Charlas de Mercado

U.S. Natural Gas Futures Give Back Some Gains -- Market Talk

24 dic 2025, 17:20 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Tech, Media & Telecom Roundup: Market Talk

24 dic 2025, 17:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

24 dic 2025, 17:08 UTC

Adquisiciones, fusiones, absorciones

This Biotech Stock Soars 39%. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24 dic 2025, 16:53 UTC

Adquisiciones, fusiones, absorciones

Nike Climb Boosts Dow, S&P 500 -- WSJ

24 dic 2025, 16:31 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

ServiceNow Gets Top-Tier Asset and Talent With Armis Buy -- Market Talk

24 dic 2025, 16:28 UTC

Adquisiciones, fusiones, absorciones

Lam Research Is at All-Time Highs. Its CEO Just Sold $27 Million Worth of Stock. -- Barrons.com

24 dic 2025, 16:17 UTC

Charlas de Mercado

Dollar Stable as U.S. Layoffs Remain at Bay -- Market Talk

24 dic 2025, 15:33 UTC

Adquisiciones, fusiones, absorciones

Nike Shares Get a Lift After Apple's Tim Cook Doubles His Personal Stake -- WSJ

24 dic 2025, 15:30 UTC

Adquisiciones, fusiones, absorciones

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 dic 2025, 15:19 UTC

Adquisiciones, fusiones, absorciones

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 dic 2025, 14:49 UTC

Adquisiciones, fusiones, absorciones

Mexico's Ollamani Sells Stake in Azteca Stadium

24 dic 2025, 14:19 UTC

Charlas de Mercado

U.S. Natural Gas Futures Move Lower After Big Jump -- Market Talk

24 dic 2025, 14:08 UTC

Adquisiciones, fusiones, absorciones

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 dic 2025, 14:06 UTC

Charlas de Mercado

Oil Futures Edge Up on Geopolitical Risk Premium -- Market Talk

24 dic 2025, 13:24 UTC

Charlas de Mercado

Canada's Economy Needs More Help Amid Dismal GDP Report -- Market Talk

24 dic 2025, 12:59 UTC

Adquisiciones, fusiones, absorciones

This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24 dic 2025, 12:51 UTC

Adquisiciones, fusiones, absorciones

Disney Could Be the Real Winner from the Warner Takeover Battle. Here's Why. -- Barrons.com

24 dic 2025, 12:38 UTC

Adquisiciones, fusiones, absorciones

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

Comparación entre iguales

Cambio de precio

Ascendis Pharma A-S ADR Esperado

Precio Objetivo

By TipRanks

25.9% repunte

Estimación a 12 meses

Media 263.42 USD  25.9%

Máximo 325 USD

Mínimo 220 USD

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ascendis Pharma A-S ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

13 ratings

13

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

157.66 / 167.29Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Strong Bullish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
help-icon Live chat